Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease
News published by Insmed Incorporated concerning ARIKAYCE, administered by the Lamira® Nebulizer System based on eFlow® Technology platform.